Hawaii Biotech, Inc.

Description

Mr. Clements has over 20 years of experience in molecular biology and the development of recombinant protein expression systems. Mr. Clements received his M.S. degree in Biochemistry from the University of Hawaii at Manoa, where his studies focused on the molecular genetics of toxin production in plant pathogenic bacteria. He then joined Hawaii Biotech in 1987. Since then he has worked on a variety of projects involving molecular genetics and has extensive experience in the expression of recombinant proteins in heterologous host cell systems.

Dr. Winship has wide experience in drug and device development from concept through Pharm/Tox, CMC, Regulatory and FDA clinical trials phase I-IV. Dr. Winship has been a pharmaceutical executive with experience in both small life science firms and large pharmaceutical companies. He has successfully developed and completed both development plans and commercialization strategies. He has conducted or participated in clinical trials for vaccines, antibodies, cancer, allergy, cytokines, and small molecules (caspase inhibitors). In addition, he is experienced in medical affairs, filing INDs and NDAs.

Dr. Elliot Parks is President & CEO of Hawaii Biotech Inc., and brings to the company over 25 years experience in academic research, biomedical product development, executive management, and life science investing. He is also a Managing Director at Hamilton BioVentures, has broad experience and personal knowledge of best practices in corporate governance, and brings this background to the HBI Board. Dr. Parks was CEO of Myelos Neurosciences and has served on the board of several private companies including Idun Pharmaceuticals and Transcept Pharmaceuticals.

Larry Knutson has 30 years of experience in executive and financial management positions in private and public U.S. and international corporations. Combined with this experience, Mr. Knutson has owned and assisted in start-up, high growth and initial IPO companies. His areas of expertise include mergers and acquisitions, due diligence, financial planning and financial turn-around assistance. Mr. Knutson has also served as Director of Acquisitions for a private investment fund responsible for all due diligence, analysis and investment documentation. Mr.

Dr. Elliot Parks brings over twenty-five years in biomedical research, product development, executive management, and international venture capital experience to the company. During that time he has had extensive experience in successfully and repeatedly translating important basic research science into commercial products. He was the founding CEO of Myelos Neurosciences a venture-backed, clinical stage biologics company sold to Savient, a NASDAQ listed firm. Prior to Myelos, Dr.

Fact sheet

Products & services

Similar companies nearby